Robust enrollment of 173 patients across dose escalation and expansion cohorts, with objective responses observed across five tumor types
JK06 continued to demonstrate a highly differentiated MMAE safety profile with predominantly low-grade, manageable treatment-related adverse events (TRAEs) at doses selected for expansion cohorts
Objective response rate (ORR) of 50% (5 of 10) among response-evaluable squamous non-small cell lung cancer (NSCLC) patients treated at the 4.5 mg/kg dose; overall disease control rate (DCR) of 94% (16 of 17) across all response-evaluable squamous NSCLC patients
Durable anti-tumor activity also observed in non-squamous and EGFR-mutant NSCLC, multiple breast cancer subtypes, and additional 5T4-expressing solid tumors
GAITHERSBURG, Md., May 30, 2026–(BUSINESS WIRE)–Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced updated data from the Phase 1/2 study of JK06, a 5T4-targeted antibody drug conjugate (ADC), in patients with unresectable locally advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC) and breast cancer. The data are being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, Illinois.
Link: https://ca.finance.yahoo.com/news/salubris-biotherapeutics-announces-updated-phase-183000883.html